Medtronic stock wins new CPT codes for two devices

Published on 10/04/2026 at 11:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medtronic received new CPT codes on October 1, 2026, supporting two device programs. Fiscal Q1 revenue rose 13.7 percent to USD 9.76 billion.

Isometrische 3D-Grafik der medizintechnischen Wertschöpfungskette von Rohstoff bis Klinik — Medtronic plc (ISIN IE00BTN1Y115) isometrische Grafik visualisiert Wertschöpfungskette von Rohstoff bis Krankenhaus schematisch, Illustration mit AI erstellt.

Medtronic plc stock (ISIN IE00BTN1Y115) was last at USD 86.38 on the NYSE on October 2, 2026 at 4:00 p.m. ET, down 0.07 percent for the session. The latest company catalyst is a reimbursement milestone: PR Newswire reported on October 1, 2026, that the American Medical Association approved Category I CPT codes for Medtronic's Altaviva and Symplicity Spyral systems.

Two devices gain permanent codes

The codes replace Category III codes and take effect in January 2028. Altaviva treats urge urinary incontinence, while Symplicity Spyral is a renal denervation system for uncontrolled hypertension.

The approval can support physician payment and commercial payer discussions, but the company release also states that the codes do not determine coverage, reimbursement, clinical superiority or patient access. That distinction keeps the event commercially relevant without turning it into an immediate revenue guarantee.

Revenue beat supports higher guidance

Medtronic's fiscal Q1 2027 revenue reached USD 9.76 billion, up 13.7 percent year over year and 3.0 percent above consensus, while adjusted EPS rose to USD 1.45 from the USD 1.39 estimate, according to Yahoo Finance on September 9, 2026.

Management raised fiscal 2027 organic revenue growth guidance to 7.25 percent-7.75 percent from 6.75 percent-7.25 percent and adjusted EPS guidance to USD 5.94-6.00 from USD 5.90-6.00. The quarter included an extra fiscal week that added USD 570 million to revenue, making the reported growth rate harder to repeat.

Analysts see room above USD 100

MarketBeat reported on October 3, 2026, that Medtronic carried a Moderate Buy consensus from 28 analysts, with an average price target of USD 103.92. The target stands 20.3 percent above the USD 86.38 reference price, while the stock remains 18.8 percent below its 52-week high of USD 106.33.

Dividend date approaches

Medtronic's market capitalization was USD 110.6 billion on October 2, 2026, with 34,596,650 shares traded. A company filing published by StockTitan states that the USD 0.72 quarterly dividend is payable on October 16, 2026, to shareholders of record on September 25, 2026.